ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Artificial Intelligence Based Dosing of Tacrolimus in Liver Transplantation: Prospective, Randomized Phase 2 Trial

A. Zarrinpar1, C. Ho2, C. Warren1, J. Khong2, M. Lee2, S. Duarte1, K. Andreoni1, M. Johnson1, N. Battula3, D. McKimmy1, T. Beduschi1

1Surgery, University of Florida, Gainesville, FL, 2Mechanical and Aerospace Engineering, University of California, Los Angeles, CA, 3Surgery, University of Oklahoma, Oklahoma City, OK

Meeting: 2022 American Transplant Congress

Abstract number: 540

Keywords: Dosage, Immunosuppression, Liver transplantation

Topic: Clinical Science » Organ Inclusive » 72 - Machine Learning, Artificial Intelligence and Social Media in Transplantation

Session Information

Session Name: Machine Learning, Artificial Intelligence and Social Media in Transplantation

Session Type: Rapid Fire Oral Abstract

Date: Tuesday, June 7, 2022

Session Time: 5:30pm-7:00pm

 Presentation Time: 6:20pm-6:30pm

Location: Hynes Room 210

*Purpose: Inter- and intra-individual variability in calcineurin dose requirements necessitates empirical clinician-titrated dosing that frequently results in deviation from target ranges, particularly during the critical early post-transplant period. We have developed an artificial intelligence-based approach, Phenotypic Personalized Medicine (PPM), to individualize drug dosing.

*Methods: In this single-center, randomized, partially blinded trial, participants were assigned immediately prior to liver transplantation 1:1 to standard-of-care clinician-guided dosing or PPM-guided dosing. Blood tacrolimus trough levels were measured daily until patient discharge. The primary outcome measure was fraction of days with large (> 2 ng/ml) deviations from target range. Secondary outcomes included post-transplant length of stay, fraction of days outside-of-target-range, mean area-under-the-curve outside-of-target-range, graft rejection, graft failure, death, infections, nephrotoxicity, or neurotoxicity. Patients were followed until discharge from hospital.

*Results: Sixty-two patients were screened and randomized. 31 were assigned to the control group and 31 to the PPM group. Fraction of post-transplant days with large deviation from target range was higher in the standard-of-care group than in the PPM group (38.4 ± 27.4% versus 24.2 ± 19.1%; P=0.03). Median length of stay was longer in the standard-of-care group than the PPM group [15 days (IQR 10.5-20.5) versus 10 days (IQR 8-12); P=0.003]. There were no significant differences in fraction of days outside-of-target-range, mean area-under-the-curve outside-of-target-range, graft rejection, graft failure, death, infections, nephrotoxicity, or neurotoxicity. No tacrolimus dosing related adverse events occurred during the trial.

*Conclusions: In this randomized prospective clinical trial of AI-based personalized dosing of tacrolimus in patients after liver transplantation, PPM-guided dosing resulted in a lower fraction of inpatient days where the tacrolimus trough blood levels had a large deviation from the target range. PPM patients also had 33% shorter post-transplant length of stay than patients receiving standard-of-care tacrolimus dosing.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Zarrinpar A, Ho C, Warren C, Khong J, Lee M, Duarte S, Andreoni K, Johnson M, Battula N, McKimmy D, Beduschi T. Artificial Intelligence Based Dosing of Tacrolimus in Liver Transplantation: Prospective, Randomized Phase 2 Trial [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/artificial-intelligence-based-dosing-of-tacrolimus-in-liver-transplantation-prospective-randomized-phase-2-trial/. Accessed May 9, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences